Enhertu - Drug Monograph

Comprehensive information about Enhertu including mechanism, indications, dosing, and safety information.

Introduction

Enhertu (fam-trastuzumab deruxtecan-nxki) is a groundbreaking antibody-drug conjugate (ADC) developed for targeted cancer therapy. Approved by the FDA in 2019, it represents a significant advancement in the treatment of HER2-positive cancers. This innovative therapy combines a humanized anti-HER2 monoclonal antibody with a potent topoisomerase I inhibitor payload, offering a targeted approach to cancer treatment with enhanced efficacy compared to traditional therapies.

Mechanism of Action

Enhertu operates through a sophisticated multi-step mechanism: 1. Target Binding: The trastuzumab component binds specifically to HER2 receptors on cancer cell surfaces 2. Internalization: The drug-receptor complex undergoes receptor-mediated endocytosis 3. Intracellular Processing: Lysosomal enzymes cleave the tetrapeptide-based linker 4. Payload Release: DXd (a derivative of exatecan) is released intracellularly 5. Cytotoxic Action: DXd inhibits topoisomerase I, causing DNA single-strand breaks and apoptosis 6. Bystander Effect: The membrane-permeable payload can affect adjacent tumor cells, including those with lower HER2 expression

Indications

FDA-approved indications include:

  • HER2-positive unresectable or metastatic breast cancer after prior anti-HER2-based regimens
  • HER2-low metastatic breast cancer (IHC 1+ or IHC 2+/ISH-negative) after prior chemotherapy
  • HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after prior trastuzumab-based regimen
  • HER2-mutant metastatic non-small cell lung cancer (NSCLC)

Dosage and Administration

Standard dosing: 5.4 mg/kg administered intravenously every 3 weeks Administration guidelines:
  • Pre-medicate with corticosteroids, antipyretics, and antihistamines
  • Infuse over 90 minutes (±15 minutes) for first infusion
  • Subsequent infusions may be administered over 30 minutes if prior infusions were tolerated
  • Do not administer as IV push or bolus
Dose modifications:
  • ILD/pneumonitis: Permanently discontinue for Grade 2 or higher
  • Neutropenia: Withhold until resolved to ≤Grade 1, then resume at same or reduced dose
  • Thrombocytopenia: Withhold until resolved to ≤Grade 1, then resume at reduced dose
Special populations:
  • Renal impairment: No dose adjustment recommended for mild to moderate impairment
  • Hepatic impairment: Not recommended for total bilirubin >3 × ULN or AST >3 × ULN
  • Geriatric: No dose adjustment required

Pharmacokinetics

Absorption: Administered intravenously, achieving complete bioavailability Distribution:
  • Steady-state volume of distribution: ~3.5 L
  • Plasma protein binding: DXd is 92-96% bound
  • Crosses blood-brain barrier to a limited extent
Metabolism:
  • Trastuzumab component: Proteolytic degradation
  • DXd payload: Primarily metabolized by CYP3A4
Elimination:
  • Half-life: ~5.7 days for trastuzumab deruxtecan
  • Clearance: ~0.42 L/day
  • Excretion: Primarily hepatic (feces), with minimal renal elimination

Contraindications

1. History of severe hypersensitivity reactions to fam-trastuzumab deruxtecan-nxki or any component 2. Pregnancy (based on mechanism of action and animal data) 3. Concurrent use with strong CYP3A4 inhibitors (unless absolutely necessary)

Warnings and Precautions

Boxed Warning:
  • Interstitial lung disease (ILD)/pneumonitis: Can be severe and fatal. Incidence: ~12%, with fatal cases occurring in 1.1% of patients
  • Embryo-fetal toxicity: Can cause fetal harm
Additional warnings:
  • Neutropenia: Grade 3-4 occurs in ~19% of patients
  • Left ventricular dysfunction: Monitor LVEF at baseline and during treatment
  • Nausea/vomiting: Prophylactic antiemetics recommended

Drug Interactions

Significant interactions:
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase DXd exposure → avoid concurrent use
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May decrease DXd efficacy → monitor closely
  • Other myelosuppressive agents: Additive bone marrow suppression → monitor blood counts

Adverse Effects

Most common (≥20%):
  • Nausea (79%)
  • Fatigue (59%)
  • Vomiting (47%)
  • Alopecia (46%)
  • Constipation (35%)
  • Decreased appetite (32%)
  • Anemia (31%)
  • Neutropenia (29%)
  • Diarrhea (29%)
  • Thrombocytopenia (26%)
Serious adverse events:
  • ILD/pneumonitis (12%)
  • Severe neutropenia (19%)
  • Left ventricular dysfunction (2.1%)
  • Severe nausea/vomiting (4%)

Monitoring Parameters

Baseline assessment:
  • HER2 status confirmation
  • LVEF measurement (ECHO or MUGA scan)
  • Complete blood count with differential
  • Comprehensive metabolic panel
  • Pregnancy test in women of reproductive potential
During treatment:
  • CBC with differential: Prior to each dose
  • LVEF: Every 3 months during treatment
  • Pulmonary symptoms: Monitor continuously for cough, dyspnea, fever
  • Liver function tests: Regularly during treatment
  • Signs of infusion reactions: During and after infusion
Post-treatment:
  • Continue cardiac monitoring for at least 4 months after last dose
  • Monitor for delayed adverse effects

Patient Education

Key points to discuss:

1. Pregnancy prevention: Use effective contraception during and for 7 months after treatment 2. Lung symptoms: Report immediately any new or worsening cough, shortness of breath, or fever 3. Infusion reactions: Understand potential symptoms and reporting procedures 4. Nausea management: Adhere to prescribed antiemetic regimen 5. Blood count monitoring: Understand importance of regular blood tests 6. Cardiac symptoms: Report chest pain, palpitations, or swelling in extremities 7. Fertility implications: Discuss fertility preservation options before treatment 8. Administration schedule: Maintain regular treatment appointments

Lifestyle considerations:
  • Maintain adequate hydration
  • Practice good nutrition despite appetite changes
  • Use sun protection (increased photosensitivity risk)
  • Avoid grapefruit products (may affect drug metabolism)

References

1. FDA Prescribing Information: Enhertu (fam-trastuzumab deruxtecan-nxki). 2023 2. Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610-621 3. Shitara K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419-2430 4. NCCN Guidelines: Breast Cancer Version 3.2023 5. Li BT, et al. Trastuzumab Deruxtecan in HER2-Mutant Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2022;386(3):241-251 6. American Society of Clinical Oncology (ASCO) Guidelines: Management of HER2-Positive Breast Cancer. 2022 7. European Society for Medical Oncology (ESMO) Guidelines: Metastatic Breast Cancer. 2021

Note: This monograph provides general information. Treatment decisions should be made in consultation with oncology specialists based on individual patient characteristics and current clinical guidelines.

Medical Disclaimer

The information provided in this article is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

The content on MedQuizzify is designed to support, not replace, the relationship that exists between a patient and their healthcare provider. If you have a medical emergency, please call your doctor or emergency services immediately.

How to Cite This Article

admin. Enhertu - Drug Monograph. MedQuizzify [Internet]. 2025 Sep 07 [cited 2025 Sep 08]. Available from: http://medquizzify.pharmacologymentor.com/blog/drug-monograph-enhertu

Enjoyed this post?

Subscribe to our newsletter and get more educational insights, quiz tips, and learning strategies delivered weekly to your inbox.